002653 海思科
已收盘 02-03 15:00:00
资讯
新帖
简况
海思科（002653）披露部分5%以上股东之一致行动人股份减持计划预披露公告，2月2日股价下跌0.85%
证券之星 · 02-02 22:47
海思科（002653）披露部分5%以上股东之一致行动人股份减持计划预披露公告，2月2日股价下跌0.85%
2月2日增减持汇总：顺丰控股等8股增持 海思科等2股减持（表）
新浪证券 · 02-02 21:57
2月2日增减持汇总：顺丰控股等8股增持 海思科等2股减持（表）
海思科(002653.SZ)股东拟合计减持不超0.89%股份
智通财经 · 02-02 20:42
海思科(002653.SZ)股东拟合计减持不超0.89%股份
股市必读：海思科（002653）1月30日董秘有最新回复
证券之星 · 02-02 03:54
股市必读：海思科（002653）1月30日董秘有最新回复
海思科：公司2025年年度报告的预约披露时间为2026年4月13日
证券之星 · 01-30
海思科：公司2025年年度报告的预约披露时间为2026年4月13日
海思科（002653）披露2026年第一次临时股东会决议公告，1月28日股价上涨0.66%
证券之星 · 01-28
海思科（002653）披露2026年第一次临时股东会决议公告，1月28日股价上涨0.66%
海思科公布国际专利申请：“一种毒蕈碱M4受体激动剂及其用途”
证券之星 · 01-24
海思科公布国际专利申请：“一种毒蕈碱M4受体激动剂及其用途”
海思科（002653）披露增加临时提案并取消部分议案暨股东会补充通知，1月16日股价上涨0.19%
证券之星 · 01-16
海思科（002653）披露增加临时提案并取消部分议案暨股东会补充通知，1月16日股价上涨0.19%
海思科（002653）披露控股股东部分股份质押展期，1月13日股价下跌2.35%
证券之星 · 01-13
海思科（002653）披露控股股东部分股份质押展期，1月13日股价下跌2.35%
海思科：1月10日召开分析师会议，东方证券、国泰海通等多家机构参与
证券之星 · 01-12
海思科：1月10日召开分析师会议，东方证券、国泰海通等多家机构参与
1月7日海思科涨6.80%，中欧医疗健康混合A基金重仓该股
证券之星 · 01-07
1月7日海思科涨6.80%，中欧医疗健康混合A基金重仓该股
海思科(002653.SZ)：HSK39297片上市许可获受理
智通财经 · 01-06
海思科(002653.SZ)：HSK39297片上市许可获受理
海思科(002653.SZ)：“HSK50042”、“HSK55879”创新药IND申请获受理
智通财经 · 2025-12-30
海思科(002653.SZ)：“HSK50042”、“HSK55879”创新药IND申请获受理
海思科(002653.SZ)获得创新药HSK46575片新增适应症IND申请受理
智通财经 · 2025-12-22
海思科(002653.SZ)获得创新药HSK46575片新增适应症IND申请受理
海思科（002653）股东范秀莲质押236万股，占总股本0.21%
证券之星 · 2025-12-19
海思科（002653）股东范秀莲质押236万股，占总股本0.21%
海思科(002653.SZ)定增股票申请获深交所审核通过
智通财经 · 2025-12-18
海思科(002653.SZ)定增股票申请获深交所审核通过
海思科(002653.SZ)：多项药物临床试验获批准
智通财经 · 2025-12-16
海思科(002653.SZ)：多项药物临床试验获批准
海思科（002653）披露向特定对象发行股票审核问询函回复更新公告，12月15日股价下跌3.0%
证券之星 · 2025-12-15
海思科（002653）披露向特定对象发行股票审核问询函回复更新公告，12月15日股价下跌3.0%
海思科(002653.SZ)：安瑞克芬注射液被新增纳入国家医保目录
智通财经 · 2025-12-08
海思科(002653.SZ)：安瑞克芬注射液被新增纳入国家医保目录
海思科（002653）披露控股股东部分股份解除质押，12月1日股价下跌0.45%
证券之星 · 2025-12-01
海思科（002653）披露控股股东部分股份解除质押，12月1日股价下跌0.45%
加载更多
公司概况
公司名称：
海思科医药集团股份有限公司
所属行业：
医药制造业
上市日期：
2012-01-17
主营业务：
海思科医药集团股份有限公司的主营业务是新药研发、生产制造、推广营销业务。公司的主要产品是环泊酚注射液、苯磺酸克利加巴林胶囊、考格列汀片、安瑞克芬注射液。公司荣获2024年中国医药研发产品线“最佳工业企业”奖项。荣获“2024年度中国医药工业主营业务收入前100位企业”第88名。
发行价格：
20.00
{"stockData":{"symbol":"002653","market":"SZ","secType":"STK","nameCN":"海思科","latestPrice":47.5,"timestamp":1770102204000,"preClose":50.25,"halted":0,"volume":9018352,"delay":0,"changeRate":-0.0547,"floatShares":483000000,"shares":1120000000,"eps":0.2759,"marketStatus":"已收盘","change":-2.75,"latestTime":"02-03 15:00:00","open":50.13,"high":50.25,"low":46.72,"amount":430000000,"amplitude":0.0702,"askPrice":47.54,"askSize":1,"bidPrice":47.5,"bidSize":47,"shortable":0,"etf":0,"ttmEps":0.2759,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1770168600000},"marketStatusCode":5,"adr":0,"adjPreClose":50.25,"symbolType":"stock","openAndCloseTimeList":[[1770082200000,1770089400000],[1770094800000,1770102000000]],"highLimit":55.28,"lowLimit":45.23,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1119917970,"isCdr":false,"pbRate":13.31,"roa":"--","peRate":172.163827,"roe":"7.08%","epsLYR":0.35,"committee":-0.44918,"marketValue":53196000000,"turnoverRate":0.0187,"status":1,"floatMarketCap":22954000000},"requestUrl":"/m/hq/s/002653","defaultTab":"news","newsList":[{"id":"2608860933","title":"海思科（002653）披露部分5%以上股东之一致行动人股份减持计划预披露公告，2月2日股价下跌0.85%","url":"https://stock-news.laohu8.com/highlight/detail?id=2608860933","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608860933?lang=zh_cn&edition=full","pubTime":"2026-02-02 22:47","pubTimestamp":1770043635,"startTime":"0","endTime":"0","summary":"截至2026年2月2日收盘，海思科报收于50.25元，较前一交易日下跌0.85%，最新总市值为562.76亿元。近日，海思科发布《关于部分5%以上股东之一致行动人股份减持计划的预披露公告》。公告显示，截至公告披露日，股东郝聪梅持有公司股份3,518,000股，占总股本0.31%；杨飞持有42,442,286股，占总股本3.79%。郝聪梅为持股5%以上股东郑伟之配偶，杨飞为持股5%以上股东范秀莲之女。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020200039557.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0033","002653","BK0188","BK0077","BK0028","BK0239"],"gpt_icon":0},{"id":"2608862376","title":"2月2日增减持汇总：顺丰控股等8股增持 海思科等2股减持（表）","url":"https://stock-news.laohu8.com/highlight/detail?id=2608862376","media":"新浪证券","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608862376?lang=zh_cn&edition=full","pubTime":"2026-02-02 21:57","pubTimestamp":1770040620,"startTime":"0","endTime":"0","summary":"炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 据统计，2月2日，盘后乐鑫科技、天合光能、顺丰控股、凌云光、中国中冶、歌尔股份、极米科技、美的集团披露增持情况。包括钧崴电子、海思科在内的2家A股上市公司披露减持情况。\n\n\n\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-02-02/doc-inhkmwpy7862574.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["06936","IE0003851619.USD","BK0232","IE00B12V2V27.USD","BK0077","LU0405327494.USD","BK0197","002653","BK0188","IE00BYQNZ168.SGD","002352","LU0405327148.USD","IE0003795394.USD","LU2213484517.USD","LU1781817850.SGD","BK1151","BK0033","BK0028","LU1580142542.USD","IE00BYTNYN87.SGD","BK0239","BK0187","BK0196"],"gpt_icon":0},{"id":"2608869164","title":"海思科(002653.SZ)股东拟合计减持不超0.89%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2608869164","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608869164?lang=zh_cn&edition=full","pubTime":"2026-02-02 20:42","pubTimestamp":1770036158,"startTime":"0","endTime":"0","summary":"智通财经APP讯，海思科(002653.SZ)发布公告，近日，公司收到部分5%以上股东之一致行动人郝聪梅女士、杨飞女士《关于减持公司股份计划的告知函》，郝聪梅、杨飞计划自公告披露之日起十五个交易日后的三个月内，通过大宗交易或集中竞价方式减持公司股份合计不超过1000万股，减持比例合计不超过公司总股本的0.89%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1400724.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0033","002653","BK0239","BK0188","BK0028","BK0077"],"gpt_icon":0},{"id":"2608889209","title":"股市必读：海思科（002653）1月30日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2608889209","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608889209?lang=zh_cn&edition=full","pubTime":"2026-02-02 03:54","pubTimestamp":1769975651,"startTime":"0","endTime":"0","summary":"截至2026年1月30日收盘，海思科报收于50.68元，上涨0.56%，换手率0.83%，成交量4.02万手，成交额2.06亿元。董秘最新回复投资者： 你好，贵司何时发布2025年年报？公司 2025年年度报告的预约披露时间为2026年4月13日。感谢您的关注与支持！交易信息汇总资金流向1月30日主力资金净流入425.26万元；游资资金净流出1515.12万元；散户资金净流入1089.86万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020200001817.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0188","002653","BK0239","BK0028","BK0033"],"gpt_icon":0},{"id":"2607091944","title":"海思科：公司2025年年度报告的预约披露时间为2026年4月13日","url":"https://stock-news.laohu8.com/highlight/detail?id=2607091944","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607091944?lang=zh_cn&edition=full","pubTime":"2026-01-30 15:18","pubTimestamp":1769757504,"startTime":"0","endTime":"0","summary":"证券之星消息，海思科(002653)01月30日在投资者关系平台上答复投资者关心的问题。投资者提问：你好，贵司何时发布2025年年报？海思科回复：尊敬的投资者，您好！公司 2025年年度报告的预约披露时间为2026年4月13日。感谢您的关注与支持！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026013000020157.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002653","BK0028","BK0033","BK0239","BK0077","BK0188"],"gpt_icon":0},{"id":"2606710153","title":"海思科（002653）披露2026年第一次临时股东会决议公告，1月28日股价上涨0.66%","url":"https://stock-news.laohu8.com/highlight/detail?id=2606710153","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606710153?lang=zh_cn&edition=full","pubTime":"2026-01-28 22:58","pubTimestamp":1769612292,"startTime":"0","endTime":"0","summary":"截至2026年1月28日收盘，海思科报收于50.48元，较前一交易日上涨0.66%，最新总市值为565.33亿元。该股当日开盘50.15元，最高50.66元，最低49.51元，成交额达1.01亿元，换手率为0.42%。近日，海思科医药集团股份有限公司发布2026年第一次临时股东会决议公告。股东出席情况显示，总共有445名股东参与，代表股份322,779,482股，占公司有表决权股份总数的28.8217%。两项议案均获得高比例同意，反对和弃权票占比极低。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012800043372.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0077","BK0028","BK0188","002653","BK0033"],"gpt_icon":0},{"id":"2605281715","title":"海思科公布国际专利申请：“一种毒蕈碱M4受体激动剂及其用途”","url":"https://stock-news.laohu8.com/highlight/detail?id=2605281715","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605281715?lang=zh_cn&edition=full","pubTime":"2026-01-24 08:50","pubTimestamp":1769215847,"startTime":"0","endTime":"0","summary":"证券之星消息，根据企查查数据显示海思科（002653）公布了一项国际专利申请，专利名为“一种毒蕈碱M4受体激动剂及其用途”，专利申请号为PCT/CN2025/108502，国际公布日为2026年1月15日。专利详情如下：图片来源：世界知识产权组织（WIPO）今年以来海思科已公布的国际专利申请2个，与去年同期持平。结合公司2025年中报财务数据，2025上半年公司在研发方面投入了3.42亿元，同比增59.22%。数据来源：企查查以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012400011790.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0239","BK0033","002653","BK0188","BK0028"],"gpt_icon":0},{"id":"2603799477","title":"海思科（002653）披露增加临时提案并取消部分议案暨股东会补充通知，1月16日股价上涨0.19%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603799477","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603799477?lang=zh_cn&edition=full","pubTime":"2026-01-16 22:44","pubTimestamp":1768574652,"startTime":"0","endTime":"0","summary":"截至2026年1月16日收盘，海思科报收于53.82元，较前一交易日上涨0.19%，最新总市值为602.74亿元。该股当日开盘53.73元，最高54.55元，最低53.51元，成交额达1.03亿元，换手率为0.4%。该议案已经董事会审议通过，将提交股东大会审议。同时，原定于股东会议程中的相同名称议案予以取消。本次股东会的召开时间、股权登记日及其他议程安排保持不变。现场会议将于2026年1月28日举行，网络投票将同步进行，中小投资者的表决结果将单独计票。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011600041430.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002653","BK0028","BK0188","BK0077","BK0033","BK0239"],"gpt_icon":0},{"id":"2603638324","title":"海思科（002653）披露控股股东部分股份质押展期，1月13日股价下跌2.35%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603638324","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603638324?lang=zh_cn&edition=full","pubTime":"2026-01-13 22:25","pubTimestamp":1768314316,"startTime":"0","endTime":"0","summary":"截至2026年1月13日收盘，海思科报收于54.77元，较前一交易日下跌2.35%，最新总市值为613.38亿元。该股当日开盘55.5元，最高55.5元，最低53.53元，成交额达3.41亿元，换手率为1.3%。公司近日发布公告称，控股股东王俊民将其持有的700万股公司股份办理了质押展期，占其所持股份比例1.75%，占公司总股本比例0.63%。本次质押展期的用途为自身生产经营，质权人为招商证券股份有限公司。公告显示，本次质押不涉及重大资产重组等业绩补偿义务。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011300042383.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002653","BK0077","BK0188","BK0239","BK0033","BK0028"],"gpt_icon":0},{"id":"2602513739","title":"海思科：1月10日召开分析师会议，东方证券、国泰海通等多家机构参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2602513739","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602513739?lang=zh_cn&edition=full","pubTime":"2026-01-12 18:01","pubTimestamp":1768212105,"startTime":"0","endTime":"0","summary":"证券之星消息，2026年1月12日海思科发布公告称公司于2026年1月10日召开分析师会议，东方证券、国泰海通、天风证券、财信证券、中信资管、中信建投、华泰柏瑞、招商基金、富国基金、天弘基金、大成基金、中国人寿、鹏扬基金、华宝基金、宝盈基金、信达澳亚基金、上海高毅、创金合信、中国人保、摩根基金、建信基金、工银瑞信、浦银安盛、农银汇理、招银国际参与。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011200025739.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["02611","002653","BK0028","BK0183","BK0184","BK0033","BK0239","600958","BK0012","03958","BK0276","601211","BK0188","BK0077","BK1147","BK1564","BK0201"],"gpt_icon":0},{"id":"2601782708","title":"1月7日海思科涨6.80%，中欧医疗健康混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2601782708","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601782708?lang=zh_cn&edition=full","pubTime":"2026-01-07 15:38","pubTimestamp":1767771497,"startTime":"0","endTime":"0","summary":"证券之星消息，1月7日海思科涨6.80%，收盘报56.35元，换手率1.42%，成交量6.84万手，成交额3.78亿元。根据2025基金Q3季报公募基金重仓股数据，重仓该股的公募基金共41家，其中持有数量最多的公募基金为中欧基金的中欧医疗健康混合A。中欧医疗健康混合A目前规模为169.77亿元，最新净值1.8529，较上一交易日上涨0.45%，近一年上涨21.89%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010700018106.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002653","BK0033","BK0188","BK0239","BK0028","BK0077","159760"],"gpt_icon":0},{"id":"2601862140","title":"海思科(002653.SZ)：HSK39297片上市许可获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2601862140","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601862140?lang=zh_cn&edition=full","pubTime":"2026-01-06 16:04","pubTimestamp":1767686694,"startTime":"0","endTime":"0","summary":"智通财经APP讯，海思科(002653.SZ)公告，公司子公司四川海思科制药有限公司于2026年1月6日收到国家药品监督管理局下发的《受理通知书》，相关药品名称为：HSK39297片，申请适应症为：适用于治疗既往未接受过补体抑制剂治疗的阵发性睡眠性血红蛋白尿症(PNH)成人患者。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1389263.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"海思科(002653.SZ)：HSK39297片上市许可获受理","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0028","002653","BK0077","BK0033","BK0188","BK0239"],"gpt_icon":0},{"id":"2595670427","title":"海思科(002653.SZ)：“HSK50042”、“HSK55879”创新药IND申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2595670427","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595670427?lang=zh_cn&edition=full","pubTime":"2025-12-30 16:20","pubTimestamp":1767082829,"startTime":"0","endTime":"0","summary":"智通财经APP讯，海思科 发布公告，公司子公司上海海思盛诺医药科技有限公司于近日收到国家药品监督管理局下发的《受理通知书》，涉及产品：“HSK50042”、“HSK55879”。本次申请为HSK50042片在呼吸系统疾病领域中又一新适应症的临床试验申请，有望为呼吸疾病患者提供一种高效、安全的新型治疗选择。HSK55879片是公司自主研发的具有独立知识产权的口服小分子激动剂药物，拟用于代谢系统疾病的治疗。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1387080.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IND","002653","159992","BK0033","BK0239","BK1574","BK0077","BK0028","BK0188","06978","BK1161"],"gpt_icon":0},{"id":"2593485369","title":"海思科(002653.SZ)获得创新药HSK46575片新增适应症IND申请受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2593485369","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593485369?lang=zh_cn&edition=full","pubTime":"2025-12-22 17:36","pubTimestamp":1766396197,"startTime":"0","endTime":"0","summary":"智通财经APP讯，海思科 发布公告，公司子公司辽宁海思科制药有限公司于近日收到国家药品监督管理局下发的《受理通书》，涉及药品：“HSK46575”。本次获得受理的为本品联合奥拉帕利片或联合多西他赛和泼尼松片用于前列腺癌的治疗适应症的临床试验申请。HSK46575片是公司自主研发的一种口服、强效和高选择性的小分子抑制剂，拟用于前列腺癌的治疗。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1384452.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0077","BK1574","IND","BK0239","BK0033","002653","BK0188","159992","BK0028","BK1161","06978"],"gpt_icon":0},{"id":"2592415183","title":"海思科（002653）股东范秀莲质押236万股，占总股本0.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=2592415183","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592415183?lang=zh_cn&edition=full","pubTime":"2025-12-19 00:24","pubTimestamp":1766075078,"startTime":"0","endTime":"0","summary":"证券之星消息，海思科12月19日公开信息显示，股东范秀莲向国泰海通证券股份有限公司合计质押236.0万股，占总股本0.21%。质押详情见下表：截止本公告日，股东王俊民已累计质押股份5344.0万股，占其持股总数的13.38%，股东范秀莲已累计质押股份5559.0万股，占其持股总数的25.58%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121900000239.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0077","002653","BK0028","BK0033","BK0188"],"gpt_icon":0},{"id":"2592032339","title":"海思科(002653.SZ)定增股票申请获深交所审核通过","url":"https://stock-news.laohu8.com/highlight/detail?id=2592032339","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592032339?lang=zh_cn&edition=full","pubTime":"2025-12-18 20:24","pubTimestamp":1766060647,"startTime":"0","endTime":"0","summary":"智通财经APP讯，海思科(002653.SZ)公告，公司于2025年12月18日收到深圳证券交易所上市审核中心出具的《关于海思科医药集团股份有限公司申请向特定对象发行股票的审核中心意见告知函》。深交所上市审核中心对公司提交的向特定对象发行股票的申请文件进行了审核，认为公司符合发行条件、上市条件和信息披露要求，后续深交所将按规定报中国证券监督管理委员会履行相关注册程序。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1383321.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"海思科(002653.SZ)定增股票申请获深交所审核通过","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002653","BK0077","BK0188","BK0239","BK0033","BK0028"],"gpt_icon":0},{"id":"2591604664","title":"海思科(002653.SZ)：多项药物临床试验获批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2591604664","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591604664?lang=zh_cn&edition=full","pubTime":"2025-12-16 16:11","pubTimestamp":1765872669,"startTime":"0","endTime":"0","summary":"智通财经APP讯，海思科(002653.SZ)公告，公司子公司上海海思盛诺医药科技有限公司于近日收到国家药品监督管理局下发的《药物临床试验批准通知书》，HSK45019片、HSK50042片、注射用HSK55718、HSK36357胶囊获准开展临床试验，相对应适应症分别为：炎症性肠病、呼吸系统疾病、急性疼痛、肌营养不良症。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1382056.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"海思科(002653.SZ)：多项药物临床试验获批准","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0028","BK0077","BK0188","BK0033","002653","BK0239"],"gpt_icon":0},{"id":"2591475306","title":"海思科（002653）披露向特定对象发行股票审核问询函回复更新公告，12月15日股价下跌3.0%","url":"https://stock-news.laohu8.com/highlight/detail?id=2591475306","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591475306?lang=zh_cn&edition=full","pubTime":"2025-12-15 22:41","pubTimestamp":1765809668,"startTime":"0","endTime":"0","summary":"截至2025年12月15日收盘，海思科报收于53.06元，较前一交易日下跌3.0%，最新总市值为594.23亿元。公司近日发布公告称，其已于2025年7月23日收到深圳证券交易所出具的关于公司申请向特定对象发行股票的审核问询函。本次向特定对象发行股票事项尚需通过深交所审核，并获得中国证监会同意注册，最终能否实施及审批时间存在不确定性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121500036467.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002653","BK0033","BK0188","BK0239","BK0028","BK0077"],"gpt_icon":0},{"id":"2589325385","title":"海思科(002653.SZ)：安瑞克芬注射液被新增纳入国家医保目录","url":"https://stock-news.laohu8.com/highlight/detail?id=2589325385","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589325385?lang=zh_cn&edition=full","pubTime":"2025-12-08 11:48","pubTimestamp":1765165721,"startTime":"0","endTime":"0","summary":"智通财经APP讯，海思科 发布公告，国家医保局、人力资源社会保障部于2025年12月7日发布了《关于印发<国家基本医疗保险、生育保险和工伤保险药品目录>以及<商业健康保险创新药品目录>>的通知》。公司的环泊酚注射液成功续约，安瑞克芬注射液被新增纳入《国家医保目录》。公司目前共有包括环泊酚注射液、安瑞克芬注射液、苯磺酸克利加巴林胶囊、考格列汀片在内的四个1类创新药被纳入国家医保目录。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1378671.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","BK0033","BK0077","002653","BK0028","BK0188"],"gpt_icon":0},{"id":"2588776140","title":"海思科（002653）披露控股股东部分股份解除质押，12月1日股价下跌0.45%","url":"https://stock-news.laohu8.com/highlight/detail?id=2588776140","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588776140?lang=zh_cn&edition=full","pubTime":"2025-12-01 22:55","pubTimestamp":1764600903,"startTime":"0","endTime":"0","summary":"截至2025年12月1日收盘，海思科报收于59.55元，较前一交易日下跌0.45%，最新总市值为666.91亿元。公司近日发布公告，控股股东王俊民先生近期解除部分股份质押。本次合计解除质押股份1,000万股，占其持有股份的2.50%，占公司总股本的0.89%。其中480万股因到期解除质押，质权人为平安证券股份有限公司；520万股经协商提前解除质押，质权人为国泰海通证券股份有限公司。截至公告日，王俊民累计质押股份5,344万股，占其所持股份的13.38%，占公司总股本的4.77%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120100037950.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002653","BK0077","BK0188","BK0239","BK0033","BK0028"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1770126349650,"stockEarnings":[{"period":"1week","weight":-0.0042},{"period":"1month","weight":-0.0208},{"period":"3month","weight":-0.0675},{"period":"6month","weight":-0.0729},{"period":"1year","weight":0.5808},{"period":"ytd","weight":-0.0208}],"compareEarnings":[{"period":"1week","weight":-0.0283},{"period":"1month","weight":0.0118},{"period":"3month","weight":0.014},{"period":"6month","weight":0.1051},{"period":"1year","weight":0.2354},{"period":"ytd","weight":0.0118}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"海思科医药集团股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"12894人(较上一季度增加12.87%)","perCapita":"37477股","listingDate":"2012-01-17","address":"西藏自治区山南市乃东区泽当镇三湘大道17号","registeredCapital":"111991万元","survey":" 海思科医药集团股份有限公司的主营业务是新药研发、生产制造、推广营销业务。公司的主要产品是环泊酚注射液、苯磺酸克利加巴林胶囊、考格列汀片、安瑞克芬注射液。公司荣获2024年中国医药研发产品线“最佳工业企业”奖项。荣获“2024年度中国医药工业主营业务收入前100位企业”第88名。","listedPrice":20},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"海思科(002653)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供海思科(002653)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"海思科,002653,海思科股票,海思科股票老虎,海思科股票老虎国际,海思科行情,海思科股票行情,海思科股价,海思科股市,海思科股票价格,海思科股票交易,海思科股票购买,海思科股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"海思科(002653)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供海思科(002653)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}